||Ibrutinib is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
||RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
||CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
||Vemurafenib (PLX4032, RG7204) is a novel and potent B-RafV600E inhibitor (IC50 of 31 nM, in the cell-free assay). Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downs
||CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
||PLX4720 is a specific and effective inhibitor of B-RafV600E (IC50=13 nM).
||Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
||Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This preven
||CHMFL-BMX-078 is a highly potent and selective type II irreversible?BMX?kinase inhibitor with an?IC50?of 11 nM.
||Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to c-Yes, Lyn, Fyn, Fgr, Blk and Lck; less active for Abl and EGFR (L858R and L861Q).
||LFM-A13（IC50=2.5 μM），a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases，such as JAK1, JAK2, HCK, EGFR, and IRK.
||ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
||PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
||Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B ?lymphocytes and macrophages. Preclinical research suggests it may be therapeutically